TB-500 is a synthetic fragment of Thymosin Beta-4 (T4) - a naturally occurring 43-amino-acid protein found in virtually every human tissue
A Longevity Pro Panel that includes fasting insulin, HbA1c, and inflammatory markers provides the biomarker foundation to assess whether a MOTS-c protocol is producing measurable metabolic improvements over a 12-week cycle
A 35-year-old CrossFit competitor in Vancouver underwent rotator cuff repair surgery four weeks ago

Medical history and medication review to flag any interactions or contraindications before prescribing Goal-specific protocol selection based on injury location, duration, and severity rather than a one-size-fits-all 500 mcg recommendation Written reconstitution and injection instructions with the exact mL and unit markings for the patients specific vial and prescribed dose Injection training for self-administration patients, either in-clinic or via telehealth video walkthrough Week-four check-in to assess response, adjust dose or frequency if needed, and confirm the patient is completing the cycle correctly Pharmacy-grade 503A product with verified purity, sterility, and potency from an FDA-registered compounding pharmacy For patients who have never injected a peptide before, we also review the BPC-157 benefits and mechanism in detail before starting the protocol so the patient understands what the peptide does, what to expect during the cycle, and what results realistically look like at four, eight, and twelve weeks

While this reclassification primarily targeted licensed compounding pharmacies, it sent a clear regulatory signal to the broader research vendor market: peptide compounds were attracting federal scrutiny at an unprecedented level
The cancelled Phase I trial that would have tested oral BPC-157 in 42 healthy volunteers never published results, leaving that data inaccessible